Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Neil Desai Sells 40,000 Shares

Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Neil Desai sold 40,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $1.71, for a total transaction of $68,400.00. Following the completion of the transaction, the chairman now owns 1,171,543 shares of the company’s stock, valued at approximately $2,003,338.53. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Neil Desai also recently made the following trade(s):

• On Monday, August 5th, Neil Desai sold 5,652 shares of Aadi Bioscience stock. The shares were sold at an average price of $1.34, for a total transaction of $7,573.68.
• On Thursday, August 1st, Neil Desai sold 15,415 shares of Aadi Bioscience stock. The shares were sold at an average price of $1.50, for a total transaction of $23,122.50.
• On Monday, July 1st, Neil Desai sold 31,348 shares of Aadi Bioscience stock. The shares were sold at an average price of $1.45, for a total transaction of $45,454.60.

Aadi Bioscience Stock Performance

NASDAQ AADI opened at $1.83 on Friday. Aadi Bioscience, Inc. has a one year low of $1.21 and a one year high of $6.29. The company’s 50 day moving average price is $1.53 and its 200 day moving average price is $1.79. The firm has a market capitalization of $44.93 million, a price-to-earnings ratio of -0.72 and a beta of 0.69.

Aadi Bioscience (NASDAQ:AADI) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.17. The company had revenue of $6.18 million for the quarter, compared to analyst estimates of $6.33 million. Aadi Bioscience had a negative net margin of 274.77% and a negative return on equity of 66.67%. During the same quarter last year, the firm posted ($0.67) earnings per share. Sell-side analysts forecast that Aadi Bioscience, Inc. will post -2.02 EPS for the current fiscal year.

Institutional Trading of Aadi Bioscience

A number of hedge funds have recently made changes to their positions in AADI. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Aadi Bioscience during the second quarter valued at approximately $37,000. Marquette Asset Management LLC acquired a new stake in shares of Aadi Bioscience during the first quarter worth approximately $135,000. Acuitas Investments LLC grew its position in shares of Aadi Bioscience by 10.8% during the second quarter. Acuitas Investments LLC now owns 352,483 shares of the company’s stock worth $515,000 after buying an additional 34,344 shares in the last quarter. Finally, Decheng Capital LLC acquired a new stake in shares of Aadi Bioscience during the fourth quarter worth approximately $1,063,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Aadi Bioscience in a research note on Wednesday, August 21st. Piper Sandler Companies cut shares of Aadi Bioscience from an “overweight” rating to a “neutral” rating and set a $1.75 target price on the stock. in a research report on Tuesday, August 27th. Piper Sandler cut shares of Aadi Bioscience from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $5.00 to $1.75 in a research report on Tuesday, August 27th. TD Cowen cut shares of Aadi Bioscience from a “buy” rating to a “hold” rating in a research report on Wednesday, August 21st. Finally, Jefferies Financial Group cut shares of Aadi Bioscience from a “buy” rating to a “hold” rating and decreased their target price for the stock from $11.00 to $1.50 in a research report on Wednesday, August 21st. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $10.25.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.